Market atlas / Antioxidant / Nrf2 / Nordihydroguaiaretic acid

Nordihydroguaiaretic acid (NDGA)

traditional-to-validatedsmall-moleculeantioxidantlipoxygenase-inhibitionanti-inflammatory● oxidative-stress

Stage by geography

signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUS

MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS

What each market approved it for

Market	Stage	Since	Indication / class / form
US	preclin	2016-01-01	not published

Biomarker trends

no biomarker readings yet

Studies

The studies on Nordihydroguaiaretic acid, what they found, in whom and how strongly, are on its evidence page, each linked to its source.

Connections

no connections yet

Trajectory

2016

ProfileNordihydroguaiaretic acid (NDGA)

PMID:27312235 · human-confirmed

2016

MarketUS: preclinical (NIA ITP animal program)

PMID:27312235 · human-confirmed

Get into the weeds: raw observations + provenance

ndga_facets  2026-07-12  kind=facets  verify=H
   NDGA facets (creosote-bush lignan; classification pending curator review)
   source PMID:27312235  https://doi.org/10.1111/acel.12496

ndga_us  2026-07-12  kind=geography_stage  verify=H
   NIA Interventions Testing Program (US), murine lifespan stage
   source PMID:27312235  https://doi.org/10.1111/acel.12496